189 related articles for article (PubMed ID: 16397211)
1. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer.
Fiegl H; Millinger S; Goebel G; Müller-Holzner E; Marth C; Laird PW; Widschwendter M
Cancer Res; 2006 Jan; 66(1):29-33. PubMed ID: 16397211
[TBL] [Abstract][Full Text] [Related]
2. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia.
Arafah M
Turk Patoloji Derg; 2012; 28(1):38-43. PubMed ID: 22207430
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
4. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen.
Widschwendter M; Siegmund KD; Müller HM; Fiegl H; Marth C; Müller-Holzner E; Jones PA; Laird PW
Cancer Res; 2004 Jun; 64(11):3807-13. PubMed ID: 15172987
[TBL] [Abstract][Full Text] [Related]
5. HER-2/neu expression in primary and metastatic breast cancer.
Lower EE; Glass E; Blau R; Harman S
Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
[TBL] [Abstract][Full Text] [Related]
6. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
Dowsett M; Harper-Wynne C; Boeddinghaus I; Salter J; Hills M; Dixon M; Ebbs S; Gui G; Sacks N; Smith I
Cancer Res; 2001 Dec; 61(23):8452-8. PubMed ID: 11731427
[TBL] [Abstract][Full Text] [Related]
7. Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
Feng W; Shen L; Wen S; Rosen DG; Jelinek J; Hu X; Huan S; Huang M; Liu J; Sahin AA; Hunt KK; Bast RC; Shen Y; Issa JP; Yu Y
Breast Cancer Res; 2007; 9(4):R57. PubMed ID: 17764565
[TBL] [Abstract][Full Text] [Related]
8. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Christiaens MR; Vergote I
Breast Cancer Res Treat; 2005 May; 91(1):81-7. PubMed ID: 15868434
[TBL] [Abstract][Full Text] [Related]
9. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway.
Witters L; Engle L; Lipton A
Oncol Rep; 2002; 9(6):1163-6. PubMed ID: 12375012
[TBL] [Abstract][Full Text] [Related]
10. Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications.
Ciocca DR; Gago FE; Fanelli MA; Calderwood SK
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):32-40. PubMed ID: 17049840
[TBL] [Abstract][Full Text] [Related]
11. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
12. Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts.
Stark A; Lu M; Mackowiak P; Linden M
Breast J; 2005; 11(3):183-7. PubMed ID: 15871703
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
14. Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer.
Barrow TM; Barault L; Ellsworth RE; Harris HR; Binder AM; Valente AL; Shriver CD; Michels KB
Int J Cancer; 2015 Aug; 137(3):537-47. PubMed ID: 25560175
[TBL] [Abstract][Full Text] [Related]
15. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
[TBL] [Abstract][Full Text] [Related]
16. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
[TBL] [Abstract][Full Text] [Related]
17. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
19. Expression of E-cadherin and c-erbB-2/HER-2/neu oncoprotein in high-grade breast cancer.
Turashvili G; Bouchalova K; Bouchal J; Kolar Z
Cesk Patol; 2007 Jul; 43(3):87-92. PubMed ID: 17821836
[TBL] [Abstract][Full Text] [Related]
20. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody.
Witters LM; Kumar R; Chinchilli VM; Lipton A
Breast Cancer Res Treat; 1997 Jan; 42(1):1-5. PubMed ID: 9116313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
